about
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomasThe 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatmentDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaINI1 mutations in meningiomas at a potential hotspot in exon 9Primary T-cell lymphoma of the central nervous system.Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature.Laser-assisted microdissection, techniques and applications in pathology (review).Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.Loss of Mpdz impairs ependymal cell integrity leading to perinatal-onset hydrocephalus in mice.Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity.Epigenomic alterations define lethal CIMP-positive ependymomas of infancyIntracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme.Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas.Identification of diagnostic serum protein profiles of glioblastoma patientsPROX1 is a predictor of survival for gliomas WHO grade IIAlterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review).Analysis of the RET, GDNF, EDN3, and EDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease.Oligodendrogliomas: impact of molecular genetics on treatment.Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma.The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial.Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasiaR132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma.Rint1 inactivation triggers genomic instability, ER stress and autophagy inhibition in the brain.Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG.The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Neuroradiology of central neurocytoma.Brain metastases: pathobiology and emerging targeted therapies.Interlaboratory comparison of IDH mutation detection.Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells.Expression of BRAF V600E mutant protein in epithelial ovarian tumors.A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens.Tweety-Homolog 1 Drives Brain Colonization of Gliomas.Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs.BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
P50
Q24671002-A3720681-468D-4852-A2BF-40980AB82728Q28474942-990D70C8-2C1D-457A-8382-BAD7F4A54558Q29616862-968F3F3F-3B43-4B82-9FCA-8BB55308E9F7Q30486830-CD3D4E2B-A0AA-4E71-8D45-345577215E52Q30666967-1FD25540-BD0C-479C-BBB7-BE40D7F16A4FQ30993716-FBEE2CEA-B61C-41E9-A674-2863CBC818EEQ33213567-097DCE4D-CE23-4F3B-89B3-6BBC4D693B30Q33572246-9F90DEA2-3719-48DC-A5FE-77431818697DQ33863489-4669A2E8-42E2-4F11-B421-7230E8BB30F2Q33917715-6EBE8DD1-D665-49F3-9490-59A0A3AE6681Q34240198-4E8404B7-06B4-406E-9BF0-EBF05FD6DBEAQ34537954-3CF44A1D-3411-471F-8E09-E1C1E6ACD61DQ34722450-09CB5F35-799A-4333-9EF8-E7CFEDB7B3E3Q34981475-89E709F9-DBA5-47B1-87CF-4022D623E875Q35034643-E7C0F508-B615-4ED2-915C-A948879422B8Q35215122-469154D3-5E9C-4228-95F5-B113FE61139EQ35363393-D378F846-6D27-4E36-9D83-4B0BDEB92E8EQ36190210-D6D9FFD6-32AC-430B-87DD-380B45136B95Q36347228-B1C8BFFC-6E92-453A-AD92-CA1B1FAD3E53Q36544494-B916CB91-A8FD-403D-A7A3-01A80641AE83Q36663610-7FF336ED-104D-4412-8F66-A803BD7C4D96Q36694219-DACD244D-E1CD-441F-A0AB-04D96B96EC29Q36942437-FAB822A8-D690-45B4-A561-6C36B665FC87Q37032086-85CE47C8-4DF8-40AA-AFEF-5AF717AC8266Q37354009-61F2C8A1-B5AB-414F-97EB-C079ED25A2ADQ37485784-5F8A871E-DDDE-4831-A5FD-FE8DF975E602Q37553466-EF1A2378-A07D-4DB5-9337-1512762301DEQ37752135-E134FAAD-D574-4172-AA47-BF7151448AD9Q37972783-F556980A-BD9E-412B-86A3-E65EC8D4D00CQ38077475-5B3F1BDC-7DD7-4A54-AD95-19762D9DF71EQ38338448-23B14334-6671-411F-A9A6-D08BB8ED188FQ38402125-6F991660-47DC-4A90-93B0-1176FA81692AQ38487094-5A7F2E34-92A7-4302-ACA3-86D366F7E17EQ38671718-9118120C-EB8E-4431-8AFA-1951F799E0FBQ39369298-B65A39F9-D03F-427B-86A9-88F15C2A3117Q39773481-6195D276-ADC1-4C47-A3DF-CB24E23D23B8Q39963026-941D535B-735F-49D4-812E-E3DD7EF9B42BQ40180256-8CB06234-235F-4A37-B342-AB0E8C8048F4Q40209862-0868111C-C7BD-4CA1-AC2E-67D52F0D7930Q40319899-FA0966D1-86B4-4B85-A3B9-CADCB305B235
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
A von Deimling
@ast
A von Deimling
@es
Andreas von Deimling
@en
Andreas von Deimling
@nl
Andreas von Deimling
@pl
type
label
A von Deimling
@ast
A von Deimling
@es
Andreas von Deimling
@en
Andreas von Deimling
@nl
Andreas von Deimling
@pl
altLabel
A von Deimling
@en
prefLabel
A von Deimling
@ast
A von Deimling
@es
Andreas von Deimling
@en
Andreas von Deimling
@nl
Andreas von Deimling
@pl
P31
P496
0000-0002-5863-540X